Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy

Oncology Reports

Volumn 18, Issue 6, 2007, Pages 1469-1473

  Paudyal, Bishnuhari ^a   Oriuchi, Noboru ^a   Paudyal, Pramila ^a   Tsushima, Yoshito ^a   Iida, Yasuhiko ^a   Higuchi, Tetsuya ^a   Hanaoka, Hirofumi ^a   Miyakubo, Mitsuyuki ^a   Takano, Akie ^a   Ishikita, Tomohiro ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; PET; Radiofrequency ablation

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; CATHETER ABLATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; SCINTISCANNING;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECURRENCE;

EID: 38449084250     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.6.1469     Document Type: Article

References (20)

1. El Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999.
2. Bosch FX, Ribes J, Borras J and Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211, 2005.
3. Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, Paties CT, Silverman DE, Buscarini L and Percutaneous RF: Interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 167: 759-768, 1996.
4. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L and Gazelle GS: Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 214: 761-768, 2000. (Pubitemid 30115377)
5. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L and Gazelle GS: Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210: 655-661, 1999. (Pubitemid 29124024)
6. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J and Vallone P: Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 232: 381-391, 2000.
7. Kostakoglu L and Goldsmith SJ: 18F- FDG PET evaluation of the response to therapy for lymphoma and for breast, lung and colorectal carcinoma. J Nucl Med 44: 224-239, 2003.
8. 67Ga Scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 44: 198-206, 2003.
9. 18F-FDG PET improves the management of patient with small cell lung cancer. J Nucl Med 44: 1911-1916, 2003.
10. 18F-FDG PET. Ann Nucl Med 18: 409-417, 2004.
11. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K and Konishi J: In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36: 1811-1817, 1995.
12. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM and Ritter JH: Detection of primary hepatic malignancy in liver transplant candidate: prospective comparison of CT MRI, US and PET. Radiology 226: 533-542, 2003. (Pubitemid 36313446)
13. 18F-FDG PET in detecting tumour recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 20: 4453-4458, 2002.
14. Barker DW, Zagoria RJ, Morton KA, Kavanagh PV and Shen P: Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT. AJR Am J Roentgenol 184: 1096-1102, 2005. (Pubitemid 43821882)
15. Antoch G, Vogt FM, Veit P, Freudenberg LS, Blechschmid N, Dirsch O, Bockisch A, Forsting M, Debatin JF and Kuehl H: Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med 46: 520-525, 2005. (Pubitemid 43093165)
16. 18F]-fluro-2-dexoy-D-glucose using aminopolyether supported substitution. J Nucl Med 27: 235-238, 1986.
17. Donckier V, van Laethem JL, Goldman S, van Gansbeke D, Feron P, Ickx B, Wikler D and Gelin M: [F-18] FDG PET as s tool for early recognition of incomplete tumour destruction after RFA for liver metastases. J Surg Oncol 84: 215-223, 2003.
18. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT and Di Bisceglie AM: Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32: 792-797, 2000. (Pubitemid 30262739)
19. Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, Tamori A, Habu D, Takeda T, Kubo S and Ochi H: Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96: 1877-1880, 2001.
20. Hatano E, Ikai I, Higashi T, Teramukai S, Torizuka T, Saga T, Fujii H and Shimahara Y: Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 30: 1-6, 2006.